Absence of clinical safety data No Phase 1 clinical safety trial for BPC-157 has been completed and published
For the myotendinous junction, as a combination point of anatomical and structural particularities (largely reviewed in [124,125]) such a new therapy possibility might be particularly important given the still unresolved problem of being the weakest element in the muscletendon unit, (and bonetendon junctions as extremely specialized tissues in general)
Stubborn body fat, low daily energy, weight loss resistance, metabolic plateau, metabolic syndrome SLU-PP-332 "The Endurance Booster" Low physical stamina and difficulty managing weight especially in people who want to improve endurance but cant push hard enough to get there
You dont have to be miserable
Its been shown to counteract the effects of NMDA antagonists like ketamine
When telomeres become critically short, cells enter senescence or apoptosis, contributing to aging at the tissue and organ level